PULMONARY HYPERTENSION IN INTERSTITIAL LUNG DISEASE: DIAGNOSTIC AND THERAPEUTIC CHALLENGES
Article Sidebar
Main Article Content
Abstract
This article devoted to open the theme pulmonary hypertension in interstitial lung disease: diagnostic and therapeutic challenges. Moreover, the article aims to explore the current state of knowledge regarding PH in ILD, emphasizing diagnostic challenges, recent therapeutic advances, and directions for future research.
Article Details
References
Nathan, S. D., Barbera, J. A., Gaine, S. P., Harari, S., Martinez, F. J., Olschewski, H., ... & Waxman, A. B. (2021). Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. New England Journal of Medicine, 384(4), 325–334. https://doi.org/10.1056/NEJMoa2008470nejm.org
Nathan, S. D., Barbera, J. A., Gaine, S. P., Harari, S., Martinez, F. J., Olschewski, H., ... & Waxman, A. B. (2023). Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease. European Respiratory Journal, 61(6), 2202414. https://doi.org/10.1183/13993003.02414-2022publications.ersnet.org+1erj.ersjournals.com+1
King, T. E., Behr, J., Brown, K. K., du Bois, R. M., Lancaster, L., de Andrade, J. A., ... & Raghu, G. (2013). Treatment of idiopathic pulmonary fibrosis with ambrisentan: A parallel, randomized trial. Annals of Internal Medicine, 158(9), 641–649. https://doi.org/10.7326/0003-4819-158-9-201305070-00003ResearchGate+1PubMed+1
Nathan, S. D., Behr, J., Collard, H. R., Costabel, U., Hoeper, M. M., Martinez, F. J., ... & Wells, A. U. (2019). Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): A randomised, placebo-controlled phase 2b study. The Lancet Respiratory Medicine, 7(9), 780–790. https://doi.org/10.1016/S2213-2600(19)30250-4PubMed+2The Lancet+2ScienceDirect+2
Olsson, K. M., Hoeper, M. M., Pausch, C., Grünig, E., Huscher, D., Pittrow, D., ... & Gall, H. (2021). Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: Results from the COMPERA registry. European Respiratory Journal, 58(3), 2101483.